[ad_1]
<div _ngcontent-c14 = "" innerhtml = "
US dollar notes, full frame
By examining the underlying holdings of the ETFs in our ETF Channel hedge universe, we compared the price of each asset against the analyst's average target price at 12 months and calculated the weighted average implied target price of the ETF Channel. the analyst for the FNB itself. For the Health Care Sector SPDR ETF, we found that the analysts' default target price for the ETF, based on its underlying holdings, was $ 101.83 per unit.
As the XLV is trading at a recent price close to $ 92.35 per unit, this means analysts see a potential upside of 10.27% for this ETF, based on analysts' average objectives for analysts. underlying assets. Cerner, UnitedHealth Group and Vertex Pharmaceuticals are three of the underlying holdings of XLV that have significant advantages over analysts' target prices. Although CERN traded at a recent price of $ 62.74 per share, the average analyst target is 11.76% higher at $ 70.12 per share. Likewise, UNH is up 10.94% from the recent share price of $ 266.81 if the average target price of $ 296.00 per analyst is reached and analysts say they are doing so. on average expect VRTX to reach a target price of $ 198.45 per share, 10.93% higher than the recent price of $ 178.90.
Together, CERN, UNH and VRTX represent 8.98% of the Health Care Select ETF Fund. Below is a summary table of current target prices for analysts:
| first name | symbol | Recent price | Avg. 12-MB analyst. Target | % Upside to Target |
|---|---|---|---|---|
| SPDR ETF Fund of Health Choices | XLV | $ 92.35 | $ 101.83 | 10.27% |
| Cerner Corp. | CERN | $ 62.74 | $ 70.12 | 11.76% |
| UnitedHealth Group Inc. | A H | $ 266.81 | $ 296.00 | 10.94% |
| Vertex Pharmaceuticals, Inc. | VRTX | $ 178.90 | $ 198.45 | 10.93% |
Are the analysts justified in these objectives or too optimistic as to where these securities will be traded in 12 months? Do analysts have a valid rationale for their goals or lag behind recent developments in business and industry? A high price target relative to the stock price of a stock may reflect optimism about the future, but may also be a forerunner of downward price revision if goal was a relic of the past. These are questions that require additional research from investors.
Click here to discover 10 ETFs with the most favorable objectives for analysts »
">
US dollar notes, full frame
By examining the underlying holdings of the ETFs in our ETF Channel hedge universe, we compared the price of each asset against the analyst's average target price at 12 months and calculated the weighted average implied target price of the ETF Channel. the analyst for the FNB itself. For the Health Care Sector SPDR ETF, we found that the analysts' default target price for the ETF, based on its underlying holdings, was $ 101.83 per unit.
As the XLV is trading at a recent price close to $ 92.35 per unit, this means analysts see a potential upside of 10.27% for this ETF, based on analysts' average objectives for analysts. underlying assets. Cerner, UnitedHealth Group and Vertex Pharmaceuticals are three of the underlying holdings of XLV that have significant advantages over analysts' target prices. Although CERN traded at a recent price of $ 62.74 per share, the average analyst target is 11.76% higher at $ 70.12 per share. Likewise, UNH is up 10.94% from the recent share price of $ 266.81 if the average target price of $ 296.00 per analyst is reached and analysts say they are doing so. expect on average that VRTX will reach a target price of $ 198.45 per share, or 10.93% recent price of $ 178.90.
Together, CERN, UNH and VRTX represent 8.98% of the Health Care Select ETF Fund. Below is a summary table of current target prices for analysts:
| first name | symbol | Recent price | Avg. 12-MB analyst. Target | % Upside to Target |
|---|---|---|---|---|
| SPDR ETF Fund of Health Choices | XLV | $ 92.35 | $ 101.83 | 10.27% |
| Cerner Corp. | CERN | $ 62.74 | $ 70.12 | 11.76% |
| UnitedHealth Group Inc. | A H | $ 266.81 | $ 296.00 | 10.94% |
| Vertex Pharmaceuticals, Inc. | VRTX | $ 178.90 | $ 198.45 | 10.93% |
Are the analysts justified in these objectives or too optimistic as to where these securities will be traded in 12 months? Do analysts have a valid rationale for their goals or lag behind recent developments in business and industry? A high price target relative to the stock price of a stock may reflect optimism about the future, but may also be a forerunner of downward price revision if goal was a relic of the past. These are questions that require additional research from investors.
Click here to discover 10 ETFs with the most favorable objectives for analysts »
